Retatrutide side effects and results in studies
Wherever a cited study commented on tolerability, that wording is reproduced verbatim below. Human work on this scale does not pin down a safety profile.
Adverse events reported
| Event | As reported | Source |
|---|---|---|
| The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate. | Human | Jastreboff AM et al. |
| Discontinuation for adverse events was 2–5% with retatrutide and 0% with placebo. | Human | Bajaj HS et al. |
| Treatment-emergent adverse events were reported by 63% of participants on LY3437943, 60% on dulaglutide and 54% on placebo, with gastrointestinal disorders the most frequent. | Human | Urva S et al. |
Outcomes measured
No outcome data are tabulated yet.
What the studies don't show
None of that settles safety beyond the specific conditions of each trial. Confirming that the vial contains what the label states tells you nothing about whether the compound has any effect.